Clinical Trials

Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins